Adriana Sanchez
Acute Care · El Paso, TXNPI 1205127636
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.1% of the total across 461 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 37 manufacturers reported payments, led by AstraZeneca at 32.0% of the total. Among acute care clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 461 payments — averaging $23.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$4K
- GSK$2K
- Boehringer Ingelheim$1K
- Actelion Pharmaceuticals US, Inc.$636
- Mylan Specialty L.p.$542
- Merck$359
- plus $3K from 31 others
What the payments were for
- Food & beverage$10,89399%
- Education$1001%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 93 | $3,515 |
| GSK | 88 | $1,877 |
| Boehringer Ingelheim | 42 | $1,030 |
| Actelion Pharmaceuticals US, Inc. | 17 | $636 |
| Mylan Specialty L.p. | 36 | $542 |
| Merck | 22 | $359 |
| Johnson & Johnson | 18 | $335 |
| Philips North America LLC | 16 | $316 |
| EMD Serono, Inc. | 17 | $286 |
| Insmed, Inc. | 11 | $236 |
| Verona Pharma, Inc. | 9 | $180 |
| Viatris Specialty LLC | 13 | $167 |
| Novartis | 10 | $165 |
| Harmony Biosciences LLC | 6 | $162 |
| Sanofi | 8 | $158 |
| Theratechnologies Inc. | 8 | $146 |
| Baxter Healthcare | 7 | $140 |
| Advanced Respiratory, Inc | 5 | $96 |
| AbbVie | 3 | $65 |
| Grifols USA, LLC | 4 | $65 |
| Jazz Pharmaceuticals Inc. | 3 | $61 |
| Sanofi-aventis U.S. LLC | 1 | $55 |
| Regeneron Healthcare Solutions, Inc. | 2 | $54 |
| Electromed, Inc. | 7 | $51 |
| Napo Pharmaceuticals Inc | 2 | $48 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $30 |
| Boston Scientific | 1 | $26 |
| 180 Medical, Inc. | 1 | $23 |
| Mallinckrodt Hospital Products Inc. | 1 | $22 |
| Astellas Pharma US Inc | 1 | $21 |
| Liquidia Technologies, Inc. | 1 | $20 |
| Inogen, Inc. | 1 | $20 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $20 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $19 |
| Pulmonx Corporation | 1 | $19 |
| Gilead | 1 | $17 |
| United Therapeutics Corporation | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,993 in reported general payments places this provider in the 95th percentile of 2,323 acute care providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 759 | $597,914 |
| Breo ElliptaFluticasone/Vilanterol | 258 | $128,128 |
| Ambrisentan | 22 | $125,950 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 121 | $90,661 |
| Pirfenidone | 23 | $51,553 |
| Spiriva RespimatTiotropium Bromide | 61 | $40,960 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 58 | $35,315 |
| SymbicortBudesonide/Formoterol Fumarate | 118 | $35,153 |
| EliquisApixaban | 39 | $33,094 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 45 | $32,055 |
| Spiriva HandihalerTiotropium Bromide | 31 | $21,484 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 24 | $18,616 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 818 | $17,569 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 100 | $14,961 |
| Fluticasone-VilanterolFluticasone/Vilanterol | 17 | $6,204 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $1,877 | $744,6581,041 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $3,515 | $125,815239 claims |
| Boehringer IngelheimSpiriva Respimat, Combivent Respimat, Stiolto Respimat | $1,030 | $108,331164 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,323 acute care providers in Texas.
Other acute care in El Paso
- Laura WilsonEl Paso$32K
- Ahtesham AliEl Paso$14K
- Haydee BirkhimerEl Paso$10K
- Patricia DandEl Paso$9K
- Dora CarcobaEl Paso$8K
- Jennifer PilotteDallas$232K
- Christie MorrisonSan Antonio$225K
- Amanda BradleyDallas$85K
- Kim HuynhCypress$29K
- Martha LibertyDallas$28K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.